LondonNovartis will pay $1.1bn upfront for Myricx.
Myricx’s next-generation antibody-drug conjugates target cancer cells directly — research spun from Britain’s Imperial College and the Francis Crick Institute in 2019.
Switzerland’s Novartis owes a further $400 million if development milestones are met.
Sources: Financial Times News